CzeekV インデックス https://validator.w3.org/feed/docs/rss2.html 論文・技術情報追加のお知らせ Rhabdomyolysis with Co-Administration of Statins and Antiplatelet Therapies-Analysis of the WHO Pharmacovigilance Database. Ophthalmologic Complications in Coronavirus Disease 2019 Immunization: A National Vaccine Adverse Event Reporting System Analysis. Blind Spots in Therapy: Unveiling Drug-Induced Angle-Closure Glaucoma Through a National Analysis. Teprotumumab-Related Hearing Loss: A Large-Scale Analysis and Review of Voluntarily Reported Patient Complaints to the Food and Drug Administration (FDA). Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET). Comparison of Infection Risks Between Various Inhaled and Intranasal Corticosteroids: A Pharmacovigilance Analysis Based on the FAERS Database. Early surgical treatment using regional clinical pathways to reduce the length of postoperative hospital stay in hip fracture patients: A retrospective analysis using the Japanese Diagnosis Procedure Combination database. Mining and analysis of adverse events profile of Guanfacine using FDA Adverse Event Reporting System (FAERS) database. A 13-years pharmacovigilance analysis of novel hormonal agents in prostate cancer using the FDA adverse event reporting system database. Vancomycin and linezolid: severe cutaneous adverse reactions to drugs. A real-world disproportionality analysis of colchicine: data mining of the public version of FDA Adverse Event Reporting System. Anticoagulant-associated calciphylaxis: analysis of USFDA adverse event report system and clinical feature analysis of reported cases. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for ramucirumab. Adverse drug events associated with metreleptin administration: a real-world pharmacovigilance study from 2014 to 2024 using the FAERS database. The antidepressants and sexual dysfunction: a pharmacovigilance-pharmacodynamic study of the FDA adverse event reporting system. Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases. Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System. Drug-induced dementia: a pharmacovigilance analysis of the FAERS database. Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024. Gestational diabetes mellitus and subsequent cardiovascular disease in a period of rising diagnoses: Cohort study. Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study. Evaluation of the safety profile of amivantamab based on real-world evidence: a call to vigilance. A comprehensive, population level evaluation of previously reported drug triggers of pemphigus highlights immunomodulatory capacity as a common characteristic. Drug-induced skin ulcer: real-world pharmacovigilance analysis based on the FDA adverse event reporting system. Potential risk analysis of antipsychotics-related constipation from the FDA Adverse Event Reporting System. Drug-induced hypokalemia: an analytical study based on real-world drug monitoring data. A real-world pharmacovigilance analysis of the FDA adverse event reporting system database for emicizumab. Ketoacidosis associated with type 2 sodium-glucose cotransporter inhibitors (SGLT2i) in patients aged 65 and older: Evidence from the French national pharmacovigilance database. Comprehensive analysis of metformin-associated lactic acidosis: Insights from the FDA Adverse Event Reporting System (FAERS). What does data on adverse reactions reveal about benzodiazepines and suicide-related risk?: A disproportionality analysis using FDA FAERS pharmacovigilance data. A retrospective pharmacovigilance study of ocrelizumab in multiple sclerosis: Analysis of the FDA Adverse Event Reporting System (FAERS) database. Pharmacovigilance and toxicological risks associated with apitherapeutic products: a systematic overview. Mortality after broad- versus narrow-spectrum antibiotic treatment for patients with nursing and healthcare-associated pneumonia: A nationwide retrospective cohort study. Determinants of length of stay after first admission for osteoporotic proximal femoral fracture in Japan. Increased postoperative complication risk in elderly hip fracture patients with cerebrovascular disorders: A propensity score-matched nationwide cohort study. Epidemiology and Clinical Outcomes of Meningococcal Infections in Japan: A Nationwide Inpatient Database Study From 2010 to 2023. Trends of adverse event reports associated with BRAF and MEK inhibitors and combinations: a retrospective disproportionality analysis using the FDA adverse event reporting system database from 2012 to 2021. Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis. The association between colorectal cancer drugs and heart failure: a real-world pharmacovigilance study of the FAERS database. Association between three lipid-lowering drugs and amnesia: a real-world pharmacovigilance study. Drug-associated deep vein thrombosis: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database. Post-marketing safety surveillance of tarlatamab: a real-world pharmacovigilance study based on the FAERS database. Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reporting system for anticancer drug-associated interstitial lung disease. Structure-Based Prediction of QT Prolongation Risk Using Graph Neural Networks: An Integrative Approach Combining In Vitro hERG Assays and Pharmacovigilance Data. AI-Enabled Surveillance and Modelling for Counterfeit Botulinum Toxin A: Risk Projection, Patient Safety, and Systemic Reform of Pharmacovigilance. Consultation complexity and professionals consulted: a retrospective cohort study in English primary care. Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system. Safety Assessment of Glucagon-Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations. Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data.